top of page

GRO Biosciences announced a $60 million series B today to help advance its pipeline that is rooted in adding non-standard amino acid (NSAA) chemistries to therapies.

  • Jul 19, 2024
  • 1 min read

Co-founder and CEO Dan Mandell discusses the company’s approach, and describes how this will allow GRObio to advance its lead program for gout into the clinic to proof of concept, as well as expand the company’s pipeline.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page